




RealRate

PHARMACEUTICAL 2018

Skye Bioscience Inc.
Rank 340 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2018

Skye Bioscience Inc.
Rank 340 of 349

The relative strengths and weaknesses of Skye Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skye Bioscience Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 379% points. The greatest weakness of Skye Bioscience Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 1,177% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,404%, being 1,127% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	556
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	806
Liabilities, Non-Current	551
Other Assets	0
Other Compr. Net Income	0
Other Expenses	-559
Other Liabilities	0
Other Net Income	206
Property and Equipment	1.4
Research and Development	311
Revenues	0
Selling, General and Administrative Expense	3,548

Output Variable	Value in 1000 USD
Assets	557
Liabilities	1,357
Expenses	3,301
Stockholders Equity	-800
Net Income	-3,094
Comprehensive Net Income	-3,094
Economic Capital Ratio	-1,404%

